重组人p53腺病毒注射液联合化疗治疗恶性体腔积液的疗效观察

目的:评价重组人p53腺病毒注射液(rAd-p53)联合化疗治疗恶性体腔积液的疗效。方法:50例恶性体腔积液患者随机分为治疗组与对照组,治疗组行穿刺引流后腔内注射rAd-p531×1012VP,在rAd-p53注射后48h体腔内再注入顺铂60mg/m2,1次/wk,疗程3wk~4wk;对照组除不给予rAd-p53外,腔内化疗与治疗组相同。结果:治疗组与对照组有效率分别为85·7%、51·7%(P<0·05);治疗组毒副反应主要为自限性发热,12h~24h后自行恢复正常。结论:rAd-p53联合化疗控制恶性体腔积液疗效好、安全。

Treatment of Malignant Body Cavity Effusion with Recombinate Human p53 Adenovirus Injection Combining Chemotherapy: Observation of Clinical Effects

OBJECTIVE: To evaluate the clinical efficiency of recombinant adenovirus p53 injection (rAd-p53) combining chemotherapy in the treatment of malignant body cavity effusion. METHODS: 50 cases with malignant body cavity effusion were randomly divided into 2 groups. The treatment group were given intracavitary administration of rAd-p53 1 × 1012VP after puncture drainage, 48h later which were given intracavitary administration of 60mg/m2 cisplatin once a week for 3～4 weeks. The control group was given the same intracavitary therapy as the treatment group but without rAd-p53 therapy. RESULTS: The total effective rates of the treatment group and the control group were 85.7% and 51.7%(P<0.05), respe_ctively. The toxic reaction was chiefly manifested as self-limited fever and which disappeared automatically in 12～24h. CONCLUSION: It is safe and effective to use rAd-p53 in the treatment of malignant body cavity effusion.